Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Clear Cell Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04485013
What this trial is testing

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Who this might be right for
Cancer
Tizona Therapeutics, Inc 240
Testing effectiveness (Phase 2)Looking for participantsNCT06265025
What this trial is testing

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerMalignant MelanomaColorectal Cancer+3 more
GeneMedicine Co., Ltd. 125
Early research (Phase 1)Looking for participantsNCT04777994
What this trial is testing

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Who this might be right for
Advanced Solid Tumor Cancer
Calico Life Sciences LLC 248
Early research (Phase 1)Study completedNCT01625351
What this trial is testing

CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Who this might be right for
Ewing SarcomaGastrointestinal TumorGerm Cell Tumor+10 more
St. Jude Children's Research Hospital 23
Testing effectiveness (Phase 2)UnknownNCT02886897
What this trial is testing

Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaBladder Cancer+3 more
Sun Yat-sen University 50
Early research (Phase 1)Study completedNCT01391143
What this trial is testing

Safety Study of MGA271 in Refractory Cancer

Who this might be right for
Prostate CancerMelanomaRenal Cell Carcinoma+4 more
MacroGenics 179
Early research (Phase 1)Study completedNCT02835833
What this trial is testing

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Who this might be right for
Renal Cell CarcinomaColorectal AdenocarcinomaNon-squamous Non-small Cell Lung Cancer+2 more
University of Alabama at Birmingham 21
Testing effectiveness (Phase 2)Ended earlyNCT00651482
What this trial is testing

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Who this might be right for
Kidney NeoplasmsKidney (Renal Cell) Cancer
Sandy Srinivas 10
Testing effectiveness (Phase 2)Study completedNCT00089648
What this trial is testing

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Pfizer 61
Early research (Phase 1)Ended earlyNCT00492440
What this trial is testing

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Kidney CancerMelanoma (Skin)
Cytheris SA 9
Testing effectiveness (Phase 2)WithdrawnNCT00556205
What this trial is testing

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Massachusetts General Hospital
Early research (Phase 1)Looking for participantsNCT07072234
What this trial is testing

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell CarcinomaPhase 1Growth Factor
M.D. Anderson Cancer Center 30
Early research (Phase 1)Looking for participantsNCT06910657
What this trial is testing

IDOV-Immune for Advanced Solid Tumors

Who this might be right for
Colorectal CancerPancreatic CancerMelanoma+13 more
ViroMissile, Inc. 78
Testing effectiveness (Phase 2)Ended earlyNCT00788125
What this trial is testing

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+8 more
City of Hope Medical Center 7
Testing effectiveness (Phase 2)Study completedNCT00866320
What this trial is testing

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Who this might be right for
Kidney Cancer
Case Comprehensive Cancer Center 49
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Not applicableWithdrawnNCT00499291
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Who this might be right for
Cancer
Eastern Cooperative Oncology Group
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Early research (Phase 1)Not Yet RecruitingNCT07686744
What this trial is testing

Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaAdvancedRecurrent+1 more
Jian Lin 8
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Next Page